DOCSLIB.ORG

Comparative Antihypertensive Efficacy of Olmesartan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Antihypertensive Efficacy of Olmesartan Journal of Human Hypertension (2002) 16 (Suppl 2), S17–S23 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists S Oparil Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA Hypertension is a major risk factor for cardiovascular gest that they are beneficial for controlling target organ morbidity and mortality. Effective control of elevated damage that is related to hypertension. Furthermore, blood pressure (BP) has been shown to reduce this risk. unlike ACE inhibitors, these agents have a side-effect Early studies of risk reduction assumed that the mech- profile that is similar to that of placebo. Based on their anism by which BP was lowered had little impact on the efficacy in controlling hypertension and their wider benefit obtained. Recent evidence, however, suggests health benefits, together with minimal side effects, that agents that inhibit the renin-angiotensin system angiotensin II (A II) receptor blockers should be con- may be particularly beneficial. The results of the recent sidered as first-line agents for the treatment of hyper- Heart Outcomes Prevention Evaluation (HOPE) trial sug- tension, particularly in patients with other cardiovascu- gest that angiotensin-converting enzyme (ACE) inhibi- lar risk factors. Preliminary evidence suggests that tors have a greater impact on cardiovascular morbidity olmesartan, an A II receptor blocker currently being and mortality than would be anticipated from their anti- evaluated for approval for clinical use, may provide anti- hypertensive effects alone. Angiotensin receptor block- hypertensive efficacy that is superior to other members ers, the other major class of antihypertensive drugs that of the class. inhibit the renin-angiotensin system, have not been Journal of Human Hypertension (2002) 16 (Suppl 2), S17– widely tested in outcomes trials, but early results sug- S23. DOI: 10.1038/sj/jhh/1001394 Keywords: antihypertensive agents; angiotensin II; renin-angiotensin system; olmesartan Introduction doubles the risk of coronary heart disease in both genders.2 Before the results of the Framingham Heart Study Hypertension is generally defined as a systolic BP became available, there was little consensus regard- (SBP) higher than 140 mm Hg and/or a diastolic BP ing the pathophysiological importance of elevated (DBP) higher than 90 mm Hg, but numerous studies blood pressure (BP), or the necessity for treatment have shown that the relationship between BP and of this condition, which was usually regarded as 1 cardiovascular disease is positive and continuous asymptomatic and benign. As a result of subsequent over a wide range of BPs.3 For example, in the Mul- extensive epidemiological research, hypertension is tiple Risk Factor Intervention Trial (MRFIT), a study now recognised as a major risk factor for cardio- that followed almost 348000 men at high risk for vascular morbidity and mortality. 11.6 years, the relative risk of death from coronary Data from the Framingham Heart Study reveal the heart disease increased gradually from 1.0 in sub- 2 magnitude of the risk imposed by hypertension. jects with a baseline SBP lower than 112 mm Hg to Figure 1 shows results of 36 years of follow-up in 2 3.7 in subjects with a baseline SBP of at least 151 subjects aged 35–64 years at enrolment. In this mm Hg.4 The relationship between DBP and cardio- study, hypertension was defined as a BP higher than vascular disease was similar. Using data from nine 140/90 mm Hg. Men who are hypertensive by this prospective observational studies that included definition are four-times more likely to experience a 420000 subjects, MacMahon and co-workers calcu- stroke or cardiac failure than normotensive control lated that the risk of stroke and coronary heart dis- subjects. Among hypertensive women, the relative ease increases gradually over a DBP range of 76–105 risk for these conditions is 3. Hypertension also mm Hg.3 The relative risk of stroke increased 10- to 12-times over this BP range.3 These findings suggest Correspondence: S Oparil, Division of Cardiovascular Disease, that the risk ratios derived from the Framingham University of Alabama at Birmingham, 1034 Zeigler Research data should be regarded as conservative estimates Building, 933 South 19th Street, Birmingham, AL 35294, USA. when assessing a patient with a substantial elevation E-mail: soparilȰuab.edu in BP.2 Antihypertensive efficacy of olmesartan S Oparil S18 Figure 1 Effect of hypertension on relative risk of cardiovascular disease in subjects aged 35–64 years from 36 years of follow-up in the Framingham Heart Study. Hypertension was defined as a BP Ͼ140/90 mm Hg. ‘Coronary disease’ includes myocardial infarction, angina pectoris, sudden death, other coronary deaths, and coronary insufficiency syndrome. (Reproduced with permission from Refer- ence 2.) Treatment of hypertension reduces cardiovascular complications. In the United King- cardiovascular risk dom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes were assigned to tight (Ͻ150/85 Lowering BP is extremely effective in reducing the mm Hg) or less tight (Ͻ180/105 mm Hg) control of incidence of cardiovascular disease in hypertensive BP.11 The mean BPs achieved in these two groups populations. Collins et al5 reviewed the results of 14 were 144/82 mm Hg and 154/87 mm Hg, respect- unconfounded randomised trials involving 37000 ively. Patients who were held to the more stringent middle-aged hypertensive subjects who had a mean BP goals experienced a significant reduction in the treatment duration of 5 years. They estimated that risk of stroke (44%) and cardiac failure (56%) com- the average difference in DBP between the subjects pared with patients with the less tight goals. Dia- allocated to antihypertensive treatment and those betes-related end points were also reduced by 24% allocated to the control groups was 5–6 mm Hg. This in the tight-control group compared with the group difference was associated with reductions of 42% with less tight control, and diabetes-related deaths and 14% in the risks of stroke and coronary heart were reduced by 32%.11 disease, respectively. Among patients with nephropathy, lower mean Antihypertensive treatment also has substantial arterial pressures are associated with slower benefits in elderly hypertensive patients, many of declines in renal function.12 Lazarus et al13 showed whom have isolated systolic hypertension. In the that tight control of BP substantially reduces the risk Systolic Hypertension in the Elderly Program of a cardiovascular event in patients with renal fail- (SHEP),6 the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension),7 the Medical ure. Analysing data from 585 chronic renal failure Research Council (MRC) trial of treatment of hyper- patients, these authors found that each 1 mm Hg tension in older adults,8 and the Systolic Hyperten- increase in SBP was associated with a 1.35-times sion in Europe (Syst-Eur)9 trials, elderly hyperten- greater risk of hospitalization for cardiovascular or sive patients were randomized to active treatments cerebrovascular disease. or placebo. Active treatments were associated with Despite the universally acknowledged benefitof a reduction of 25% in the risk of coronary artery dis- BP control, overall management of hypertension is ease, and with reductions of 25–47% in the risk of poor. Data from phase 2 of the National Health and stroke. A recent review of the SHEP data showed Nutrition Examination Survey (NHANES) III show that antihypertensive treatment reduced the risks of that effective BP control is achieved in only 27% of both haemorrhagic and ischaemic stroke.10 In all hypertensive subjects.14 In the population of hyper- trials, reductions in the overall incidence of cardio- tensive adults, 32% are unaware of their condition vascular endpoints ranged from 17 to 40%.6–9 and 41% are aware but are either untreated or Antihypertensive treatment is particularly ben- uncontrolled despite treatment.14 Although these eficial among particular subgroups of the hyperten- disappointing statistics can be attributed partly to sive population, such as patients with diabetes or lack of aggressive management by physicians,15 poor nephropathy, who are at particularly high risk of patient compliance is also a major factor.16 Incon- Journal of Human Hypertension Antihypertensive efficacy of olmesartan S Oparil S19 venient dosing regimens and adverse events are both mately 5 mm Hg when administered over a pro- known to reduce compliance with antihyperten- longed treatment period. A prolonged reduction in sive therapy.16,17 pressure of this magnitude has been associated with a 21% reduction in the risk of coronary heart dis- 3 Comparative efficacy of antihypertensive ease, and a 34% reduction in the risk of stroke. This calculation of expected risk reduction assumes that drugs the mechanism by which BP is lowered is unimport- Only a few trials have directly compared the efficacy ant. Evidence is emerging, however, that this may of different classes of antihypertensive drug. In the not be the case. Treatment of Mild Hypertension Study (TOMHS), 902 men and women with mild hypertension were Effect of inhibition of the renin- randomized to treatment with a diuretic (chlor- ␤ ␣ angiotensin system on cardiovascular thalidone), a -blocker (acebutolol),
Load more

Recommended publications
  • Key Features of Candesartan Cilexetil and a Comparison with Other Angiotensin II Receptor Antagonists
    Journal of Human Hypertension (1999) 13, (Suppl 1), S3–S10 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists PS Sever Imperial College of Science, Technology & Medicine at St Mary’s Hospital, London, UK Current research on angiotensin II AT1-receptor antag- in patients with essential hypertension. Candesartan onists (AIIRAs) and selected studies presented at the cilexetil has a rapid onset of action (approximately 80% recent symposium held in Amsterdam, The Netherlands, of total blood pressure reduction within the first 2 on 6 June 1998, titled ‘Angiotensin II Receptor Antagon- weeks) and dose-dependent effects on blood pressure, ists are NOT all the Same’ are reviewed. AIIRAs offer a is comparable in efficacy to a number of classes of anti- number of potential advantages over alternative antihy- hypertensives, and is effective in combination therapy pertensive agents acting via the renin-angiotensin-aldo- (eg, with hydrochlorothiazide and amlodipine). This sterone system. They combine blood pressure-lowering favourable profile may be due in part to the highly selec- effects at least equivalent to those of angiotensin-con- tive, tight binding to and slow dissociation of candesar- verting enzyme (ACE) inhibitors, coupled with placebo- tan from the AT1 receptor. Preliminary studies suggest like tolerability. Candesartan cilexetil is a novel AIIRA that candesartan cilexetil also protects end organs that has demonstrated clinical
    [Show full text]
  • Effective Dose Range of Enalapril in Mild to Moderate Essential Hypertension
    Br. J. clin. Pharmac. (1985), 19, 605-611 Effective dose range of enalapril in mild to moderate essential hypertension R. BERGSTRAND', H. HERLITZ2, SAGA JOHANSSON', G. BERGLUND2, A. VEDIN', C. WILHELMSSON', H. J. GOMEZ3, V. J. CIRILLO3 & J. A. BOLOGNESE4 'Department of Medicine, Ostra Hospital and 2Department of Medicine I, Sahlgrenska Hospital, Goteborg, Sweden and Department of 3Cardiovascular Clinical Research and 4Clinical Biostatistics, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, USA 1 The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hyper- tension. 2 Patients were randomly assigned to two of six treatments: placebo, 2.5, 5, 10, 20 and 40 mg/day of enalapril maleate. There were two 3-week treatment periods, each preceded by a 4-week, single-blind placebo washout. 3 Each dose of enalapril produced significant decreases in standing and supine systolic and diastolic blood pressure after 2 and 3 weeks of treatment. There were no significant changes on placebo. 4 There was a significant linear dose response relationship for both mean blood pressure and mean change from baseline in blood pressure (P < 0.01 for systolic and mean arterial pressure, and P < 0.05 for diastolic pressure). 5 Enalapril was associated with an increasing dose-response relationship across the 2.5- 40 mg/day range. The 2.5 mg/dose is effective in some patients; however, doses ¢ 10 mg/ day may be necessary to achieve satisfactory blood pressure control. Keywords enalapril angiotensin converting enzyme inhibitor dose-response relationship Introduction In recent years much interest has been focused with renal impairment treated with high doses of on angiotensin converting enzyme (ACE) in- captopril.
    [Show full text]
  • Diovan® Valsartan
    NDA 21-283/S-011 Page 3 T2005-02 Diovan® valsartan Tablets Rx only Prescribing Information USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, Diovan should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality. DESCRIPTION Diovan® (valsartan) is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT1 receptor subtype. Valsartan is chemically described as N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]- 4-yl]methyl]-L-valine. Its empirical formula is C24H29N5O3, its molecular weight is 435.5, and its structural formula is Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water. NDA 21-283/S-011 Page 4 Diovan is available as tablets for oral administration, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides (yellow, black and/or red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 8000, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone- secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.
    [Show full text]
  • AVAPRO Rx Only (Irbesartan) Tablets
    NDA 20-757/S-038 Page 3 ® AVAPRO Rx only (irbesartan) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality. DESCRIPTION ®* AVAPRO (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist. Irbesartan is a non-peptide compound, chemically described as a 2-butyl-3-[p-(o-1H-tetrazol-5- ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one. Its empirical formula is C25H28N6O, and the structural formula: Irbesartan is a white to off-white crystalline powder with a molecular weight of 428.5. It is a nonpolar compound with a partition coefficient (octanol/water) of 10.1 at pH of 7.4. Irbesartan is slightly soluble in alcohol and methylene chloride and practically insoluble in water. AVAPRO is available for oral administration in unscored tablets containing 75 mg, 150 mg, or 300 mg of irbesartan. Inactive ingredients include: lactose, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, poloxamer 188, silicon dioxide and magnesium stearate. CLINICAL PHARMACOLOGY Mechanism of Action Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal NDA 20-757/S-038 Page 4 cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the user Candesartan cilexetil 2 mg tablets Candesartan cilexetil 4 mg tablets Candesartan cilexetil 8 mg tablets Candesartan cilexetil 16 mg tablets Candesartan cilexetil 32 mg tablets candesartan cilexetil Read all of this leaflet carefully If you are going to have an operation, before you start taking this tell your doctor or dentist that you are medicine because it contains taking Candesartan cilexetil. This is important information for you. because Candesartan cilexetil, when - Keep this leaflet. You may need combined with some anaesthetics, to read it again. may cause an excessive drop in - If you have any further questions, blood pressure. ask your doctor or pharmacist. - This medicine has been Children and adolescents prescribed for you only. Do not Candesartan Cilexetil has been pass it on to others. It may harm studied in children. For more them, even if their signs of illness information, talk to your doctor. are the same as yours. Candesartan Cilexetil must not be - If you get any side effects, talk to given to children under 1 year of your doctor or pharmacist. This age due to the potential risk to the includes any possible side effects developing kidneys. not listed in this leaflet. See Other medicines and Candesartan section 4. cilexetil What is in this leaflet Tell your doctor or pharmacist if you 1. What Candesartan cilexetil is and are taking, have recently taken or what it is used for might take any other medicines. 2. What you need to know before you take Candesartan cilexetil Candesartan cilexetil can affect the 3.
    [Show full text]
  • BENICAR HCT Tablets
    ® BENICAR HCT Tablets (OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benicar HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION BENICAR HCT® (olmesartan medoxomil-hydrochlorothiazide) is a combination of an angiotensin II receptor antagonist (AT1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ). Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan medoxomil is 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2­ propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3­ carbonate. Its empirical formula is C29H30N6O6 and its structural formula is: Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.6. It is practically insoluble in water and sparingly soluble in methanol. Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzo-thiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and its structural formula is: 1 Reference ID: 3227549 Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.7. Hydrochlorothiazide is slightly soluble in water but freely soluble in sodium hydroxide solution. BENICAR HCT® is available for oral administration in tablets containing 20 mg or 40 mg of olmesartan medoxomil combined with 12.5 mg of hydrochlorothiazide, or 40 mg of olmesartan medoxomil combined with 25 mg of hydrochlorothiazide. Inactive ingredients include: hydroxypropylcellulose, hypromellose, lactose, low-substituted hydroxypropylcellulose, magnesium stearate, microcrystalline cellulose, red iron oxide, talc, titanium dioxide and yellow iron oxide.
    [Show full text]
  • Effects of Olmesartan Vs Irbesartan on Metabolic Parameters and Visfatin in Hypertensive Obese Women
    European Review for Medical and Pharmacological Sciences 2010; 14: 759-763 Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women D.A. DE LUIS, R. CONDE, M. GONZALEZ SAGRADO, R. ALLER, O. IZAOLA, J.L. PEREZ CASTRILLON, E. ROMERO, M.J. CASTRO Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation. Hospital Rio Hortega. RD-056/0013 RETICEF. University of Valladolid. Valladolid (Spain) Abstract. – Background: Angiotensin II reg- dence of this rising tide of obesity and associated ulates the production of adipokines. The objective pathologies has led, in the last years, to a dramat- was to study the effect of treatment with irbesartan versus olmesartan in obese hypertensive women. ic increase of researches on the role of adipose Subjects: A sample of 34 obese hypertensive tissue as an active participant in controlling the women was analyzed in a prospective way with a body’s physiology2. randomized trial. Patients were randomized to irbe- Visfatin was recently identified as a protein sartan (300 mg/day) or olmesartan (40 mg/day) for preferentially expressed in visceral adipose tis- 3 months. Weight, body mass index, blood pres- sue, compared with subcutaneous adipose tis- sure, basal glucose, insulin, total cholesterol, LDL- sue3. It can be found in skeletal muscle, liver, cholesterol, HDL-cholesterol, triglycerides, HOMA and visfatin were determined at basal time and af- bone marrow and lymphocytes, where it was ter 3 months of treatment. initially identified as pre-B-cell colony-enhanc- Results: Thirty four patients gave informed con- ing factor (PBEF). Fukuhara et al4 clearly sug- sent and were enrolled in the study.
    [Show full text]
  • AVAPRO Safely and Tablets: 75 Mg, 150 Mg, 300 Mg (3) Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ———————————— DOSAGE FORMS AND STRENGTHS ———————————— • These highlights do not include all the information needed to use AVAPRO safely and Tablets: 75 mg, 150 mg, 300 mg (3) effectively. See full prescribing information for AVAPRO. AVAPRO® (irbesartan) tablets, for oral use ——————————————— CONTRAINDICATIONS ——————————————— • Hypersensitivity to any component of this product. (4) Initial U.S. Approval: 1997 • Coadministration with aliskiren in patients with diabetes. (4) ————————————— WARNINGS AND PRECAUTIONS ————————————— WARNING: FETAL TOXICITY • Hypotension: Correct volume or salt depletion prior to administration. (5.2) See full prescribing information for complete boxed warning. • Monitor renal function and serum potassium. (5.3) • When pregnancy is detected, discontinue AVAPRO as soon as possible. (5.1, 8.1) • Drugs that act directly on the renin-angiotensin system can cause injury and death ——————————————— ADVERSE REACTIONS ——————————————— to the developing fetus. (5.1, 8.1) • Nephropathy in type 2 diabetic patients: The most common adverse reactions which were more frequent than placebo were hyperkalemia dizziness, orthostatic dizziness, and orthostatic hypotension. (6.1) —————————————— INDICATIONS AND USAGE —————————————— To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800- AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: 633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) ——————————————— DRUG INTERACTIONS ——————————————— • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated • Lithium: Risk of lithium toxicity. (7) serum creatinine, and proteinuria. (1.2) • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment.
    [Show full text]
  • Blocking the Tissue Renin-Angiotensin System: the Future Cornerstone of Therapy
    Journal of Human Hypertension (2000) 14, Suppl 2, S23–S31 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Blocking the tissue renin-angiotensin system: the future cornerstone of therapy T Unger1, M Azizi2 and GG Belz3 1Institute of Pharmacology, Christian Albrechts University, Hospitalstra␤e 4, 24105 Kiel, Germany; 2Centre D’Investigations Cliniques, Hoˆ pital Broussais, 96 Rue Didot – 75674, Paris Cedex 14, France; 3Zentrum fuer Kardiovaskulaere Pharmakologie, ZeKaPha GmbH, Mathildenstra␤e 8, D-55116, Mainz-Wiesbaden, Germany The development of angiotensin-converting enzyme antagonist, is characterised by its tight binding to and inhibitors and selective angiotensin type 1 (AT1)- slow dissociation from the AT1 receptor, and high antag- receptor antagonists has provided new insights into onistic potency, resulting in long-lasting antagonistic understanding the mechanism of the renin-angiotensin effects. It is anticipated that these pharmacological system (RAS) in the pathophysiology of cardiovascular characteristics may bring additional benefits to patients, disease. There is good evidence from meta-analyses not only for the management of essential hypertension that shows that inhibition of the RAS achieves organ but also for the management of end-organ damage. protection features that go beyond blood pressure con- Journal of Human Hypertension (2000) 14, Suppl 2, S23– trol. Candesartan cilexetil, a new angiotensin II receptor S31 Keywords: renin-angiotensin system; angiotensin-converting enzyme inhibitor; angiotensin type 1 receptor; angiotensin receptor antagonist; candesartan cilexetil Introduction Blocking the RAS in essential Hypertension is a major risk factor for myocardial hypertension infarction, stroke, and renal and peripheral vascular Angiotensin II, the key effector peptide of the RAS, disease.
    [Show full text]
  • THE DOSE an Estimation of Equivalent Doses Between Arbs and Aceis
    THE DOSE An estimation of equivalent doses between ARBs and ACEIs ARBs still currently available as of Jan 26, 2020: Twynsta (telmisartan/amlodipine): 40/5mg. 40/10mg, 80/5mg, 80mg/ 10mg Note: ~$0.73/tablet (ODB covered) Candesartan/Hydrochlorothiazide:16mg/12.5mg, 32mg/12.5mg, 32mg/25mg Irbesartan/Hydrochlorothiazide: 150/12.5mg, 300/12.5mg, 300/25mg Olmesartan/Hydrochlorothiaizde: 20/12.5mg, 40/12.5mg Valsartan/Hydrochlorothiazide: 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg, 320/25mg Note: Availability changes daily. Some pharmacies are able to get candesartan (4mg, 8mg, and 32mg) and irbesartan (300mg). Considerations Patients renal function and hepatic function should be taken into consideration Patients should have blood pressure, lytes and SCr checked with rotation from ARB to ACEI as clinically indicated in 1-4 weeks ACEIs can cause a dry cough in 5-35% of patients and carry a risk of angioedema (0.1-0.2%) Comparable dosages between ACEIs and ARBs- Summary of trials Lisinopril 20mg Enalapril 20mg Perindopril 4mg Ramipril 10mg Candesartan 16mg 8mg 16mg Irbesartan 150mg Telmisartan 80mg 40-80mg 40mg ~80mg Valsartan 160mg 80mg Note: There are variations for approximate equivalent dosages between ACEIs and ARBs in clinical trials. Approximate equivalent doses of ACEI for blood pressure lowering Drug Approximate Initial Daily Dose Usual Daily Maintenance Dose Maximum Daily Duration of Dose Dose Action Equivalence Between ACEIs Cilazapril 2.5mg 2.5-5mg 2.5-5mg dailya 10mg 12-24 hr Enalapril maleate 5mg 2.5-5mg 10-40mg daily (or divided bid)a 40mg 12-24 hr Fosinopril 10mg 10mg 10-40mg daily (or divided bid)a 40mg 24hr Lisinopril 10mg 2.5-10mg 10-40mg daily 80mg 24hr Perindopril 2mg 2-4mg 4-8mg daily 8mg 24hr Quinapril 10mg 5-10mg 10-20mg dailya 40mg 24hr Ramipril 2.5mg 1.25mg-2.5mg 2.5-10mg daily (or divided bid)a 20mg ~24hr a: Some patients may experience a diminished antihypertensive effect toward the end of a 24-hour dosing interval.
    [Show full text]
  • COZAAR (Losartan Potassium) Tablets, for Oral Use
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Increase dose to 100 mg once daily if further blood pressure These highlights do not include all the information needed to use response is needed. (2.3) COZAAR safely and effectively. See full prescribing information for COZAAR. --------------------- DOSAGE FORMS AND STRENGTHS --------------------- Tablets: 25 mg; 50 mg; and 100 mg. (3) ® COZAAR (losartan potassium) tablets, for oral use ------------------------------- CONTRAINDICATIONS ------------------------------- Initial U.S. Approval: 1995 • Hypersensitivity to any component. (4) • Coadministration with aliskiren in patients with diabetes. (4) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. ----------------------- WARNINGS AND PRECAUTIONS ----------------------- • Hypotension: Correct volume or salt depletion prior to administration When pregnancy is detected, discontinue COZAAR as soon as of COZAAR. (5.2) possible. Drugs that act directly on the renin-angiotensin system • Monitor renal function and potassium in susceptible patients. (5.3, can cause injury and death to the developing fetus. (5.1) 5.4) --------------------------- RECENT MAJOR CHANGES --------------------------- ------------------------------ ADVERSE REACTIONS ------------------------------ Warnings and Precautions Hyperkalemia (5.4) 10/2018 Most common adverse reactions (incidence ≥2% and greater than placebo) are: dizziness, upper respiratory infection, nasal congestion, ----------------------------INDICATIONS AND USAGE ---------------------------- and back pain. (6.1) COZAAR is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and To report SUSPECTED ADVERSE REACTIONS, contact Merck children greater than 6 years old. Lowering blood pressure reduces Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877- the risk of fatal and nonfatal cardiovascular events, primarily strokes 888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]